NCT02937844 - Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2019

Conditions

Glioblastoma Multiforme

Interventions

BIOLOGICAL

Anti-PD-L1 CSR T cells

Prescribed CSR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）.

DRUG

Cyclophosphamide

250 mg/m\^2, d1-3

DRUG

Fludarabine

25mg/m\^2, d1-3

Trial Locations (1)

RECRUITING

Sanbo Brain Hospital Capital Medical University, Beijing